STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders



Status:Archived
Conditions:Blood Cancer, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:March 2009
End Date:February 2011

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Twice Weekly in Subjects With Hematologic Malignancies


The purpose of this study is to characterize the safety and efficacy of STA-9090 in subjects
with hematologic malignancies.



We found this trial at
3
sites
The University of Texas Health Science Center at San Antonio, Medical Arts and Research Center
San Antonio, Texas 78229
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Memorial Sloan-Kettering Cancer Center - Basking Ridge
136 Mountainview Blvd
Basking Ridge, New Jersey 7920
(908) 542-3000
Memorial Sloan-Kettering Cancer Center - Basking Ridge At Memorial Sloan Kettering Basking Ridge, we offer...
?
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Dana-Farber Cancer Institute
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials